Published On: Sun, Jul 15th, 2018

Xencor launches phase 1 trial of XmAb20717 in advanced solid tumors

Tagged with: | | | | |

has launched a phase 1 clinical trial of its bispecific antibody , which is being developed for the treatment of multiple advanced solid tumors.

The -based biopharma company has dosed the first patient in this regard in the early-stage human trial named XmAb20717-01 (DUET-2).

DUET-2 is a multiple-dose, dose-escalation trial that will determine the safety and tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary anti-tumor activity of XmAb20717, which will be intravenously administered in patients with certain advanced solid tumors.

According to Xencor, XmAb20717 simultaneously targets PD-1 and CTLA-4 immune checkpoints.

Xencor doses first patient in Phase 1 trial of XmAb20717 in advanced solid tumors.

Xencor doses first patient in Phase 1 trial of XmAb20717 in advanced solid tumors. Photo courtesy of Daino_16/Freeimages.com

Commenting on the phase 1 DUET-2 trial of XmAb20717, Paul Foster – chief medical officer at Xencor, said: “Built on the scaffold of Xencor’s XmAb bispecific Fc domain, XmAb20717 is the most advanced candidate in our suite of tumor microenvironment activators.

“The dual blockade of PD-1 and CTLA-4 with XmAb20717 may promote superior T cell activation and proliferation compared to anti-PD-1 alone, and we look forward to studying its safety, tolerability and therapeutic activity in clinical trials.”

Xencor is looking to file investigational new drug applications for a couple of more tumor microenvironment activators – a PD-1 x ICOS bispecific antibody called XmAb23104 and a CTLA-4 x LAG-3 dual checkpoint inhibitor named XmAb22841 by the end of this year.

Headquartered in Monrovia and founded in 1997, Xencor develops engineered monoclonal antibodies that are designed to target autoimmune diseases, asthma and allergic diseases and .

Related posts